Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO)
Conditions: EGF-R Positive Non-Small Cell Lung Cancer; Non Small Cell Lung Cancer; EGFR Exon 19 Deletion; EGFR Exon 21 Mutation; EGFR G719X Intervention: Radiation: Stereotactic Body Radiation Therapy SBRT Sponsor: Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Non-Small Cell Lung Cancer | Radiation Therapy | Research | Study